The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.
2 reports, 2 independent
Updated Aug 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.Sub-event
- FDA issued a Complete Response Letter to PTC Therapeutics regarding vatiquinone for Friedreich's ataxia.Sub-event
Multiple concurrent developments: FDA CRL, PTC partnerships (Novartis, Roche), and AI stock benefits from Trump-era tariffs.1 source
Keep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyPTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. PTC Therapeutics, In
- Pharmaceutical TechnologyPTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia The US Food and Drug Administration (FDA) has rejected PTC Therapeutics’ new drug application (NDA) for vatiquinone in Friedreich's Atax